Want to see JP:9987 full AI Analyst Report?
Top Page
Suzuken Co
(9987)
Select Model
Select Model
Rating:71Outperform
Price Target:
¥5,525.00
▲(7.32% Upside)
Action:Reiterated
Date:08/17/26
Overall score is driven primarily by strong financial quality (notably the very low leverage and improving profitability), tempered by inconsistent cash-flow conversion. Valuation is supportive (low P/E and ~2% yield), while technical indicators are a near-term headwind with price below key moving averages and a negative MACD.
Positive Factors
Steady Revenue Growth
Sustained revenue expansion supports the durability of Suzuken's pharmaceutical distribution franchise. Continued demand from hospitals, clinics, and pharmacies can provide a stable operating base, even though growth is moderate rather than rapid.
Negative Factors
Volatile Cash Conversion
Large year-to-year cash-flow swings reduce confidence in earnings conversion and may reflect significant working-capital needs in pharmaceutical distribution. Recurring inventory or receivables volatility could constrain reinvestment and shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady Revenue Growth
Sustained revenue expansion supports the durability of Suzuken's pharmaceutical distribution franchise. Continued demand from hospitals, clinics, and pharmacies can provide a stable operating base, even though growth is moderate rather than rapid.
Read all positive factors
Suzuken Co (9987) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥293.02B
Dividend Yield1.94%
Average Volume (3M)161.34K
Price to Earnings (P/E)9.5
Beta (1Y)0.39
Revenue Growth4.65%
EPS Growth23.21%
CountryJP
Employees12,717
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)542.90
Shares Outstanding72,167,206
10 Day Avg. Volume159,890
30 Day Avg. Volume161,336
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)1.00
Price to Sales (P/S)0.17
P/FCF Ratio22.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥6,250.00Price Target Upside21.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)369.23
Revenue Forecast (FY)¥2.56T
Suzuken Co Business Overview & Revenue Model
Company Description
Suzuken Co., Ltd., along with its affiliated companies, operates primarily as a wholesale distributor of pharmaceuticals, serving both domestic and international markets. The company's diverse activities are organized into four distinct divisions....
How the Company Makes Money
Suzuken primarily makes money by acting as an intermediary in the pharmaceutical supply chain: it purchases pharmaceuticals and healthcare-related products from manufacturers and sells them to customers such as hospitals, clinics, and pharmacies, ...
Suzuken Co Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
92
Very Positive
Cash Flow
56
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.52T | 2.49T | 2.40T | 2.39T | 2.31T | 2.24T |
| Gross Profit | 192.61B | 192.53B | 192.23B | 185.25B | 179.69B | 167.33B |
| EBITDA | 64.86B | 66.68B | 62.39B | 51.58B | 39.48B | 32.55B |
| Net Income | 37.73B | 38.14B | 34.50B | 29.02B | 20.34B | 14.39B |
Balance Sheet | ||||||
| Total Assets | 1.20T | 1.16T | 1.11T | 1.23T | 1.15T | 1.14T |
| Cash, Cash Equivalents and Short-Term Investments | 148.78B | 141.67B | 141.58B | 242.11B | 192.70B | 201.46B |
| Total Debt | 24.38B | 0.00 | 1.80B | 1.80B | 1.80B | 1.88B |
| Total Liabilities | 779.79B | 739.75B | 706.41B | 812.26B | 734.57B | 723.65B |
| Stockholders Equity | 415.70B | 415.88B | 407.29B | 416.31B | 411.21B | 417.69B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 18.50B | -79.39B | 76.41B | 22.21B | -1.64B |
| Operating Cash Flow | 0.00 | 33.57B | -65.08B | 87.22B | 37.27B | 9.52B |
| Investing Cash Flow | 0.00 | 12.82B | 20.38B | 10.35B | -46.36B | 1.44B |
| Financing Cash Flow | 0.00 | -33.34B | -35.48B | -31.72B | -26.22B | -11.60B |
Suzuken Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ¥529.54B | 12.85 | 7.26% | 2.66% | 4.17% | 15.59% | |
71 Outperform | ¥293.02B | 9.51 | 9.19% | 2.14% | 4.65% | 23.21% | |
69 Neutral | ¥435.66B | 13.85 | 11.15% | 3.56% | 4.32% | 0.18% | |
69 Neutral | ¥516.88B | 15.70 | 10.75% | 1.91% | 12.20% | -25.42% | |
63 Neutral | ¥440.53B | 10.69 | 7.93% | 3.02% | 4.61% | 43.22% | |
54 Neutral | ¥403.30B | 23.80 | ― | 1.96% | 13.04% | -0.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:9987
Suzuken Co
5,162.00
-809.69
-13.56%
JP:2784
Alfresa Holdings
2,308.50
93.59
4.23%
JP:7459
Medipal Holdings
2,919.00
273.47
10.34%
JP:9989
Sundrug Co
3,726.00
-791.78
-17.53%
JP:7649
Sugi Holdings Co
1,330.00
-579.44
-30.35%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
4,218.00
279.84
7.11%
Suzuken Co Corporate Events
Suzuken Posts Higher Sales but Profit Decline, Affirms Outlook and Stock Split Plan
Aug 7, 2026
Suzuken reported consolidated net sales of ¥628.9 billion for the quarter ended June 30, 2026, up 6.1% year on year, but operating profit fell 25.0% to ¥4.2 billion and profit attributable to owners of parent declined 10.6% to ¥3.4 ...
Suzuken Assesses Kumamoto Quake Impact as Kumamoto Plant Halts Operations
Jul 30, 2026
Suzuken has activated emergency response headquarters across its group companies following the July 28 Kumamoto Earthquake to verify employee safety and assess operational damage. The company reports that all employees at its affected Kyushu-based...
Suzuken to Grant Restricted Treasury Shares as Long-Term Executive Incentive
Jun 24, 2026
Suzuken has approved the disposal of 36,366 treasury shares as restricted share-based compensation to its directors, executive officers, associate directors and directors of subsidiaries, at a disposal value of ¥4,977 per share, totaling appr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.